Renalytix plc (LSE: RENX)*: New laboratory facility and submission of technical review for CE MarkinghVIVO plc (AIM: HVO): hVIVO to conduct world’s first pivotal Phase III human challenge whooping cough vaccine trial for ILiAD BiotechnologiesCambridge Nutritional Sciences plc (AIM: CNSL): FY2026 Trading updateCreo Medical Group plc (AIM: CREO): Q1 2026 Trading update
22 Apr 2026
SP Angel Healthcare Conditions
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
SP Angel Healthcare Conditions
Cambridge Nutritional Sciences PLC (CNSL:LON), 2.0 | Creo Medical Group Plc (CREO:LON), 13.2 | hVIVO plc (HVO:LON), 8.8 | Renalytix Plc (RENX:LON), 1.8
- Published:
22 Apr 2026 -
Author:
Vadim Alexandre | Greg Pave -
Pages:
4 -
Renalytix plc (LSE: RENX)*: New laboratory facility and submission of technical review for CE MarkinghVIVO plc (AIM: HVO): hVIVO to conduct world’s first pivotal Phase III human challenge whooping cough vaccine trial for ILiAD BiotechnologiesCambridge Nutritional Sciences plc (AIM: CNSL): FY2026 Trading updateCreo Medical Group plc (AIM: CREO): Q1 2026 Trading update